Searched for
FDF MANUFACTURING PLANT
NATCO Pharma receives FDA Establishment Inspection Report for Visakhapatnam plantNATCO Pharma announced receiving an Establishment Inspection Report from the US FDA for its FDF Unit. The inspection took place in Vishakha...
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
These large-, mid- and small-cap stocks can give more than 20% return in 1 year, according to analystsHere’s one thing that is worth clarifying, because it is in the headlines. Large global technology companies have been announcing heavy spe...
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
5 stocks with consistent score improvement and upside potential of up to 32% in 1 year, according to analystsFor the next few weeks, the markets will readjust as business updates, which have started to arrive, and the Q2 earnings numbers roll in. C...
Stocks in news: Tata Motors, RVNL, Eicher Motors, Mazagon Dock and LupinIndian equity markets experienced volatility, with the Nifty 50 extending its losing streak for four weeks. Escalating US-Iran hostilities ...
Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...
As headwinds slow & managements become realistic, time for a relook: 5 mid-cap pharma stocks with upside potential of up to 44%Every sector goes through a phase when managements become over-optimistic, taking decisions that should have been avoided. But then, with t...
Listen beyond the noise from Trump, think beyond Nifty’s volatility: 8 mid and 1 small cap pharma stock with upside potential of up to 46%With the Nifty moving up for just two days, have we forgotten what happened to stock prices in the past six months? This is where we all ma...
Looking at mid-caps? Keep your portfolio healthy: 5 mid-cap pharma stocks with an upside potential of up to 38%Even as the bears are running wild on the street causing across-the-board damage, there are sectors that have kept them at bay. And that’s ...
Decline in rupee: Besides IT, there are other winners as well; 9 pharma stocks with an upside potential of up to 40%The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharm...
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
Comeback and re-rating supported by numbers? 5 pharma stocks with upside potential of up to 21%Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant ch...
Laurus Labs Q2 Results: Net profit nosedives 84% YoY to Rs 37 croreLaurus Labs' revenue for the quarter ended September declined 22.3% YoY to Rs 1,224 crore in Q2FY24. The company's earnings before interest...
Tailwinds at the right time: 7 pharma stocks with an upside potential up to 37 %It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case o...
For risk takers; 5 midcap and small stocks from different sectors with right levels of RoE and upside potential of up to 29%Friday’s up move in nifty might make some think that correction is over, but if one looks at the intra day move, the fall from high of the ...
How Laurus Labs capex drive can impact its margins & valuationsRise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion i...
Pharma, health, insurance & gold loan companies top picks of fund managers in AprilFunds opted for cos with cheaper valuations, cost efficiency & resilience in these times.
Indian drugmakers to pay higher facility fees on US hikeThe new rates, applicable on companies from all nations, are effective from Oct 1 and will remain in force through Sept 30, 2015, as per FD...